arthritis rheumatoid arthritis
Conditions
Interventions
The study will involve a baseline whole body macrophage PET-CT scan follow by a
clinical follow-up period of one year to assess development of clinical
arthritis at 3, 6, 9 and 12 months.
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Patients must be 18 years of age or older 2. Patients must be diagnosed with arthralgia (not secondary to trauma) by a physician 3. Patients must have a positive ACPA blood test 4. Patients must be able to adhere to the study appointments and other protocol requirements. 5. Patients must be capable of giving informed consent and the consent must have been obtained prior to the study related procedures.
Exclusion criteria
Exclusion criteria: 1. Arthritis and/or tenosynovitis as revealed by physical examination of 44 joints through the Disease Activity Score (DAS) (34) by 2 independent physicians 2. Previous corticosteroid injection in joints 3. Trauma involving joints in the 6 months prior to inclusion 4. Pregnancy or breast-feeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The diagnostic performance (PPV, NPV, sensitivity and specificity) of quantitative whole body PET and macrophage targeting for development of clinical arthritis in ACPA positive arthralgia individuals during one year follow-up. Predictive ability of PET will be regarded as clinically relevant if the positive predictive value will be equal or more than 80%. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not applicable. | — |
Countries
Netherlands
Outcome results
None listed